OncoMatch/Clinical Trials/NCT05445011
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
Is NCT05445011 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Fludarabine + Cyclophosphamide + TAA05 Cell for acute myeloid leukemia.
Treatment: Fludarabine + Cyclophosphamide + TAA05 Cell — This is a clinical trial of Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the treatment of patients with relapsed / refractory acute myeloid leukemia. The purpose is to evaluate the safety and efficacy of anti-FLT3 CAR-T cells in patients with relapsed / refractory acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
creatinine ≤ 1.5 uln
Liver function
total bilirubin ≤ 2 × uln; alt and ast ≤ 2.5 × uln; for the patients with alt and ast abnormalities caused by disease which researchers judge (e.g. liver infiltrates or bile duct obstruction), the indicators of which can be relaxed to ≤5× uln
Cardiac function
left ventricular ejection fraction ≥ 50% and echocardiography does not reveal pericardial effusions and ecg does not reveal clinically significant abnormal bands
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify